Published in The Lancet on Aug. 6, the findings could reshape treatment for patients whose cancer has recently spread and has received little or no prior systemic therapy. The results supported the U.S. Food and Drug Administration’s approval in late July of lutetium Lu-177 vipivotide tetraxetan, also known as ^177Lu-PSMA-617, for earlier use alongside an androgen receptor pathway inhibitor and androgen deprivation therapy.

Metastatic prostate cancer is commonly driven by male sex hormones, particularly testosterone and related androgens. For that reason, the standard treatment backbone has typically combined androgen deprivation therapy, which suppresses the body’s production of testosterone, with an androgen receptor pathway inhibitor, which blocks cancer cells from responding to residual hormonal signals. Although this approach can control disease for a time, resistance eventually develops in many patients. The PSMAddition trial tested whether introducing a targeted radiopharmaceutical before resistance emerges could extend that period of control.

The study enrolled more than 1,100 men with PSMA-positive metastatic prostate cancer at 169 sites in 20 countries. Approximately half received intravenous ^177Lu-PSMA-617 every six weeks in addition to androgen deprivation therapy and an androgen receptor pathway inhibitor. The other participants received the hormonal treatment combination alone, representing the previous standard of care. Patients in the control group were permitted to cross over to the three-drug regimen if their disease progressed, a design that allowed them access to the investigational treatment while preserving the trial’s ability to compare initial treatment strategies.

The radiopharmaceutical works through a molecular targeting system. PSMA is a protein found at high levels on the surface of most prostate cancer cells; according to the investigators, roughly nine in ten patients with metastatic prostate cancer have PSMA-positive tumors. ^177Lu-PSMA-617 consists of a PSMA-binding molecule chemically linked to lutetium-177, a radioactive isotope. After the drug binds to PSMA, it is taken toward or into the tumor cell, where the isotope emits beta radiation. This radiation damages nearby cellular DNA, helping destroy malignant cells while limiting exposure to tissues that carry little or no PSMA.

The trial’s primary result was radiographic progression-free survival, which measures how long patients live without visible growth or spread of cancer on imaging or death from any cause. Early addition of ^177Lu-PSMA-617 extended this interval compared with hormonal treatment alone. The investigators also reported that the drug delayed the development of castration-resistant disease, the stage at which prostate cancer continues progressing despite testosterone suppression. In addition, patients receiving the targeted radiotherapy experienced a longer interval before cancer-related symptoms involving the skeleton appeared.

Bone complications are a major concern in advanced prostate cancer because the disease frequently spreads to the skeleton. Tumors in bone can cause pain, fractures, spinal cord compression and other disabling problems. By delaying skeletal symptoms, the treatment may preserve quality of life as well as postpone the need for subsequent therapies. However, the researchers emphasized that longer follow-up is still needed to determine whether the early progression benefit will translate into a statistically confirmed improvement in overall survival.

The added treatment also brought additional side effects, as expected from a three-drug regimen that combines hormonal therapy with systemic radiation. Dry mouth was the most frequently reported adverse event, affecting 46% of patients who received ^177Lu-PSMA-617. The symptom occurs because salivary glands can express PSMA and may absorb some of the radiopharmaceutical. Fatigue was also common, reflecting the effects of both radiation and hormonal treatment. Physicians must weigh these risks against the potential benefit and monitor patients over time for less common or delayed complications.

The therapy is not suitable for every person with metastatic prostate cancer. Patients must first undergo specialized molecular imaging to confirm that their tumors contain sufficient PSMA for targeting. Administration requires nuclear medicine physicians or radiation oncologists, as well as facilities equipped to handle radioactive medicines. Treatment centers must also provide guidance on radiation safety, including precautions designed to reduce exposure to family members and others in the household. These requirements may make access more difficult for patients who live far from academic medical centers or specialized oncology programs.

The early success of ^177Lu-PSMA-617 follows earlier studies showing activity in patients whose metastatic prostate cancer had already become resistant to hormonal treatment. Its use at diagnosis represents a shift in strategy: rather than reserving targeted radiotherapy for advanced, treatment-resistant disease, clinicians may now deploy it while tumors remain more vulnerable to combined treatment. The PSMAddition investigators are continuing to analyze long-term survival and safety data. As additional molecular imaging agents and biomarker-driven therapies enter clinical practice, treatment selection is likely to become increasingly individualized, with the biology of each tumor helping determine which targeted drug is introduced, and when.

Subject of Research: Early use of targeted radionuclide therapy with ^177Lu-PSMA-617 in PSMA-positive metastatic prostate cancer.

News Publication Date: 6-Aug-2026

Web References: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy; https://news.weill.cornell.edu/news/2017/05/first-clinical-trial-of-new-targeted-molecular-therapy-in-us-takes-aim-at-incurable

References: The Lancet; PSMAddition phase 3 clinical trial.

Keywords: Prostate cancer, metastatic prostate cancer, PSMA, ^177Lu-PSMA-617, lutetium vipivotide tetraxetan, targeted radionuclide therapy, radiopharmaceuticals, androgen deprivation therapy, androgen receptor pathway inhibitors, cancer treatment

As prostate cancer predominantly affects middle-aged and elderly men, the lack of unified clinical guidelines poses significant challenges in patient care. The complexity of the disease, especially when distinguishing between localized and metastatic cases, exacerbates the urgency for informed and standardized management practices. Despite various international and domestic guidelines existing, there remains a daunting void in high-level evidence concerning crucial aspects of prostate cancer treatment. This inadequacy has led Chinese experts to unite in a concerted effort to enhance the standard of care, making timely interventions possible to improve health outcomes for patients afflicted by this disease.

The consensus, which was published on October 10, 2024, in the prestigious journal UroPrecision, reflects extensive deliberations and collective input from a panel of elite specialists, including urologists, medical oncologists, and radiologists. These experts addressed 19 pivotal questions focusing on various aspects of prostate cancer management, ranging from screening protocols and biopsy techniques to advanced treatment options for localized, locally advanced, and metastatic disease. The thorough examination of these topics demonstrates the commitment of Chinese professionals to establish a well-defined framework that clinicians can follow to navigate the complexities of prostate cancer effectively.

One of the most significant conclusions drawn from the consensus is the overwhelming support for prostate-specific antigen (PSA) screening, with a noteworthy 89% of the participating experts affirming its efficacy in reducing prostate cancer-specific mortality rates. This statistic serves as a powerful testament to the importance of early detection in combating the disease. The experts recommend initiating PSA screening at the age of 50 for men who do not have a family history of prostate cancer or carry BRCA2 mutations, thereby setting a clear benchmark for preventive healthcare practices.

In the realm of treatment strategies, the consensus advocates for the incorporation of next-generation hormonal agents in combination with androgen deprivation therapy (ADT) for patients diagnosed with high-volume metastatic castration-sensitive prostate cancer. This progressive approach emphasizes the need for advanced treatment modalities that can tackle the aggressive nature of metastatic forms of the disease. For individuals categorized as nonmetastatic castration-resistant prostate cancer patients, about 75% of experts concurred that additional assessments, such as Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT), should be pursued in cases where standard imaging fails to reveal metastasis.

This consensus reflects a significant stride toward the standardization of prostate cancer management in China, as articulated by Nianzeng Xing, the corresponding author of the study. He highlighted that this document serves as a vital reference that offers comprehensive guidance for clinicians, documenting the entire patient journey from screening to final treatment and follow-up. Such a meticulous effort underlines how experts aim to transform the management landscape of prostate cancer, providing a lifeline for patients who are grappling with the complexities of their treatment options.

Furthermore, the consensus document sets forth actionable, evidence-based recommendations engineered to support healthcare professionals in effectively navigating the challenging terrain of prostate cancer management. By highlighting critical challenges and offering a cohesive resolution through expert-driven consensus, there lies potential not only to elevate patient outcomes but also to enhance the quality of life for those battling the disease. These strategic recommendations related to both screening practices and treatment protocols stand poised to make a substantial difference in the clinical practices deployed throughout China.

The rapidly increasing incidence of prostate cancer necessitates a proactive and unified response from the medical community. The consensus created by noted specialists could serve as a vital instrument in fighting against this growing health threat, paving the way for improved care and treatment methodologies that could ultimately reduce the burden of the disease. The forward-thinking initiatives encapsulated in the consensus aim to foster a more structured approach to managing prostate cancer, all while paying careful attention to the nuances of patient care.

As the healthcare system continues to evolve, the implications of this consensus could resonate far beyond just clinical settings. By addressing pressing medical challenges through expert-driven insights, the guidelines foster a culture of collaboration and standardization that could enhance overall health outcomes for patients across China, regardless of geographic or socioeconomic barriers. The collective effort in forging this consensus illustrates a powerful commitment to advancing care standards while ensuring that healthcare professionals are equipped with the knowledge necessary to confront prostate cancer effectively.

In summation, the consensus published in UroPrecision marks a crucial advance in the discourse surrounding prostate cancer management in China. The syntheses of expert opinions and the establishment of a coherent framework signify a turning point in how clinicians will approach diagnosis, treatment, and patient follow-up strategies. The diligence shown by Chinese specialists in crafting this document embodies a proactive commitment to improving patient care and addressing the immediate needs of those affected by prostate cancer, presenting a large step forward in the quest for improved survival rates and health outcomes in the face of an escalating health challenge.

Subject of Research: Prostate Cancer Management
Article Title: Hot Issues on Chinese Expert Consensus of Prostate Cancer Management
News Publication Date: 10-Oct-2024
Web References: UroPrecision
References: DOI 10.1002/uro2.76
Image Credits: Not applicable

Keywords: Prostate cancer, PSA screening, androgen deprivation therapy, metastatic prostate cancer, clinical guidelines.